March 9, 2020 / 11:13 AM / 24 days ago

Bristol-Myers' multiple myeloma combo therapy fails late-stage study

March 9 (Reuters) - Bristol Myers Squibb Co said on Monday its combination therapy for multiple myeloma did not meet the main goal of showing an improvement in progression-free survival in newly diagnosed patients.

The trial tested a combination of the company's Empliciti, Celgene Corp's Revlimid and a corticosteroid dexamethasone, against the combination of Revlimid and dexamethasone in a late-stage study.

Bristol-Myers gained access to Revlimid through its $74 billion buyout of Celgene last year.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below